MUC16 and ovarian carcinoma: Already in 2014, this approach was used to engineer Mucin-16 (Muc16) targeting CAR-T cells to additionally secrete IL-12, leading to enhanced CAR-T-cell proliferation and prolonged persistence in an IFN-γ-dependent manner in ovarian cancer in vivo models.46